Abstract

Follicular lymphoma (FL) is an indolent cancer of mature B-cells but with ongoing risk of transformation to more aggressive histology over time. Recurrent mutations associated with transformation have been identified; however, prognostic features that can be discerned at diagnosis could be clinically useful. We present here comprehensive profiling of both tumor and immune compartments in 155 diagnostic FL biopsies at single-cell resolution by mass cytometry. This revealed a diversity of phenotypes but included two recurrent patterns, one which closely resembles germinal center B-cells (GCB) and another which appears more related to memory B-cells (MB). GCB-type tumors are enriched for EZH2, TNFRSF14, and MEF2B mutations, while MB-type tumors contain increased follicular helper T-cells. MB-type and intratumoral phenotypic diversity are independently associated with increased risk of transformation, supporting biological relevance of these features. Notably, a reduced 26-marker panel retains sufficient information to allow phenotypic profiling of future cohorts by conventional flow cytometry.

Follicular lymphoma can transform to a more aggressive histology. Here, the authors use bulk and single cell analysis to create a 26 marker panel which could be used to profile FL samples and predict the risk of transformation using flow cytometry.

Details

Title
Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk
Author
Wang, Xuehai 1 ; Nissen, Michael 1 ; Gracias, Deanne 1 ; Kusakabe, Manabu 1 ; Simkin, Guillermo 1 ; Jiang, Aixiang 2   VIAFID ORCID Logo  ; Duns, Gerben 2 ; Sarkozy, Clementine 3 ; Hilton, Laura 2   VIAFID ORCID Logo  ; Chavez, Elizabeth A. 2 ; Segat, Gabriela C. 1   VIAFID ORCID Logo  ; Wong, Rachel 1 ; Kim, Jubin 1 ; Aoki, Tomohiro 2   VIAFID ORCID Logo  ; Islam, Rashedul 4 ; May, Christina 4 ; Hung, Stacy 2 ; Tyshchenko, Kate 1 ; Brinkman, Ryan R. 1 ; Hirst, Martin 4   VIAFID ORCID Logo  ; Karsan, Aly 4   VIAFID ORCID Logo  ; Freeman, Ciara 2 ; Sehn, Laurie H. 2 ; Morin, Ryan D. 5   VIAFID ORCID Logo  ; Roth, Andrew J. 6   VIAFID ORCID Logo  ; Savage, Kerry J. 2 ; Craig, Jeffrey W. 2   VIAFID ORCID Logo  ; Shah, Sohrab P. 7 ; Steidl, Christian 2   VIAFID ORCID Logo  ; Scott, David W. 2 ; Weng, Andrew P. 1   VIAFID ORCID Logo 

 BC Cancer Agency, Terry Fox Laboratory, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000) 
 BC Cancer Agency, Lymphoid Cancer Research, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000) 
 BC Cancer Agency, Lymphoid Cancer Research, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); Institut Gustave Roussy, Drug Development Unit, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388) 
 BC Cancer Agency, Canada’s Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000) 
 BC Cancer Agency, Canada’s Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); Simon Fraser University, Department of Molecular Biology and Biochemistry, Burnaby, Canada (GRID:grid.61971.38) (ISNI:0000 0004 1936 7494) 
 BC Cancer Agency, Molecular Oncology, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000) 
 BC Cancer Agency, Molecular Oncology, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2734480579
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.